NCT06594874 - A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

January 1, 2027

Conditions

Non-Small Cell Lung CancerAdvanced Solid Tumors

Interventions

DRUG

HS-10370

HS-10370 administered orally every day

DRUG

Adebrelimab

Administered intravenously every 21 days; dose by label.

DRUG

Cisplatin

Administered intravenously every 21 days; dose by label.

DRUG

Carboplatin

Administered intravenously every 21 days; dose by label.

DRUG

Pemetrexed

Administered intravenously every 21 days; dose by label.

Trial Locations (1)

Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan